A groundbreaking clinical trial for the new immunotherapy drug to treat Type 1 diabetes (T1D) has begun in Australia.

Led by the University of Queensland’s research facility, Frazer Institute, the trial examining the drug ASITI-201 is the first of its kind in the world and has already dosed its first five participants.

The trial is also still recruiting participants but is currently limited to residents of Queensland only.

Researchers are seeking individuals over the age of 18 who have been diagnosed with Type 1 diabetes within the past five years to participate at the Translational Research Institute’s Clinical Research Facility, located at Brisbane’s Princess Alexandra Hospital.

Professor Ranjeny Thomas of Frazer Institute is leading the development of ASITI-201, a targeted immunothe

See Full Page